Protropin Articles
US FDA recalls reached all-time high in 1999
10 March 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
$180M lawsuit bill hits Genentech earnings
21 January 2000
Genentech to settle patent dispute?
18 November 1999
Genentech in patent dispute with University of California
14 October 1999
Roche reducing stake in Genentech
11 October 1999
Genentech's 1st qtr product sales leap 42%
15 April 1999
Genentech fined $50 mill by US govt
15 April 1999
Genentech fined up to $50 mill by US govt
9 April 1999
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Rituxan Revenues Boost Genentech's 2nd Quarter
14 July 1998
3rd Qtr Sales And Earnings Take A Dip At Genentech
16 October 1997
Earnings Decline At Genentech In 1st Qtr
21 April 1997
Earnings Decline At Genentech In 2nd Qtr
22 July 1996
Revenues Up But Profits Down At Genentech
22 April 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
Hoffmann-La Roche acquires rights to Genentech products
18 December 1995
Genentech And Roche Strengthen Relationship
6 November 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Genentech/Caremark Growth Hormone Trial
14 August 1995
Genentech Growth Hormone Probe Widened
17 July 1995
The Biopharmaceutical Industry To Come
17 July 1995
Questions Raised Over Genentech's Marketing
23 January 1995
Lilly And Genentech Settle Out Of Court
16 January 1995
Genentech Setback In hGH Suit
12 December 1994
FDA Broadens Genentech Probe
14 November 1994
Genentech Halts Protropin Program
17 October 1994
Genentech Presentation Pleases Analysts
17 October 1994
FDA, HHS Probe Pharmacy Promos
5 September 1994
Genentech Probed Over Growth Hormone
22 August 1994
BIOPHARMACEUTICALS MARKET GROWING FAST
13 June 1994
PROFITS MORE THAN DOUBLE AT GENENTECH
25 April 1994
GENENTECH'S hGH APPROVED IN USA
21 March 1994
"EXCELLENT"RESULTS FROM GENENTECH
24 January 1994
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
PROFITS SOAR FOR GENENTECH IN 2ND QTR
19 July 1993
GENENTECH TEMPERS PATENT POSITION
28 June 1993
ROCHE FORESEES GOOD OUTLOOK FOR 1993
3 May 1993
US 1st QTRs IN LINE WITH EARLIER WARNINGS
26 April 1993
WORLD ENDOCRINE MARKET AND FORECASTS
29 March 1993
GENENTECH FILES COMPLAINT
22 March 1993
PHARMACEUTICAL DESIGN: EPITOPE SELECTION
15 March 1993
REVENUES RISE AT GENENTECH
25 January 1993
GENENTECH'S EXPANDING PRODUCT PORTFOLIO
11 May 1992
IMPROVEMENTS IN 1ST QTR FOR US FIRMS
20 April 1992
1991 A YEAR OF STRONG GROWTH IN THE USA
27 January 1992
REVISIONS FOR US ORPHAN DRUG ACT?
27 January 1992
GENENTECH EXPECTS FLAT YEAR IN 1992
13 January 1992
Showing 1-53 of 53 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
